Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc(RIGL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
SELL
SELL for 5 days
PROFIT SINCE LAST BUY
-10.7% ▼
LAST CLOSE
$44.46
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RIGL

11/13/2026: RIGL (2-star) is a SELL. SELL for 5 days. Simulated Profits (-10.70%). Updated daily EoD!

Rigel Pharmaceuticals is a commercial-stage biotechnology company that markets small-molecule therapies for immunology and oncology. The company's core strengths lie in its proven ability to navigate regulatory hurdles and successfully launch commercial products, specifically TAVALISSE and REZLIDHIA. The primary investment story centers on the continued market adoption of its dual-product portfolio and the potential for long-term growth through pipeline expansion. Key risks include intense competition from larger pharmaceutical incumbents, product concentration, and the ongoing need for effective execution to reach sustainable profitability. This stock may suit growth-oriented investors with a high risk tolerance who are interested in the biotechnology sector's commercial development.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers growth potential through product adoption, though it carries high execution risk.
Momentum investorMixed fitMomentum is highly conditional on positive clinical data or earnings surprises.
Value investorWeak fitValuation is difficult to anchor given the company's early commercial stage and R&D-heavy business model.
Dividend investorWeak fitThe company does not pay a dividend and focuses capital on growth.
Low-risk investorWeak fitHigh volatility inherent in biotechnology stocks makes this unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks often swing wildly based on binary events like FDA decisions.
Valuation riskMedium / highIt is challenging to assign a fundamental floor to companies with high R&D dependency.
Competition risk (Major Pharma)HighLarge competitors can out-spend and out-maneuver Rigel in marketing and distribution.
Business qualityMediumThe company has proven commercial capability but maintains a narrow product base.
Dividend incomeLow / noneNo income is returned to shareholders via dividends.
Execution riskMedium / highSuccess depends on consistent sales execution and effective clinical development.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 837.18M USD
Price to earnings Ratio 2.84
1Y Target Price 64.4
Price to earnings Ratio 2.84
1Y Target Price 64.4
Volume (30-day avg) 244.4K shares
Beta 1.24
52 Weeks Range 24.95 - 52.60
Updated Date 11/14/2026
52 Weeks Range 24.95 - 52.60
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 15.64

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -12.51%
Avg. Invested days 27
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RIGL receives a 4-star rating, supported by strong unit economics, and strong company fundamentals. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
RIGL has strong overall fundamentals (5 stars), with solid financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+1999.1%) and strong cash generation (FCF margin 25.7%) are partially offset by modest insider ownership of 3.33%.

Financial Health Rating

★★★★★
RIGL's financial health is supported by strong profitability, including gross margin of 93.3% and operating margin of 42.6%. Cash strength is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is RIGL's strongest growth driver at +1999.1% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+64.1%, strong) and free-cash-flow growth (+143.5%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 90.8% and approximately 79.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.33% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 10.33%
Soleus Capital Management, L.P. 9.81%
Armistice Capital, LLC 8.90%
State Street Corp 5.54%
Vanguard Capital Management, LLC 4.18%

Unit Economics (Per $1K Revenue)

★★★★★
RIGL generates approximately $933 of gross profit, $426 of operating income, and $257 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: -201.27% (Tax Credit)

Quantitative Style Profile

★★★★★
RIGL has a high-quality, liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedQuality TiltHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product SalesRevenue generated from TAVALISSE and REZLIDHIA sales.The company relies on doctors prescribing their specific drugs to patients.
Contract Revenue/LicensingUpfront payments, milestones, and royalties from partners.The company sometimes earns money by licensing its drug technology to others.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 0.87
Actual 0.65

Profitability

Profit Margin 106.59%
Operating Margin (TTM) 26.28%

Management Effectiveness

Return on Assets (TTM) 12.35%
Return on Equity (TTM) 109.18%

Valuation

Trailing PE 2.84
Forward PE 9.56
Enterprise Value 768.83M
Price to Sales(TTM) 2.9
Enterprise Value 768.83M
Price to Sales(TTM) 2.9
Enterprise Value to Revenue 2.67
Enterprise Value to EBITDA 9.22
Shares Outstanding 18.83M
Shares Floating 14.99M
Shares Outstanding 18.83M
Shares Floating 14.99M
Percent Insiders 3.33
Percent Institutions 90.83

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.